Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Sep;55(9):2225-2232.
doi: 10.1002/ppul.24919. Epub 2020 Jul 3.

Highlights from the 2019 North American Cystic Fibrosis Conference

Jordana E Hoppe  1 , Jennifer Guimbellot  2 , Stacey L Martiniano  1 , Demet Toprak  3 , Chelsea Davis  3 , Cori L Daines  4 , Marianne S Muhlebach  5 , Charles R Esther Jr  5 , Elisabeth P Dellon  5
Affiliations
Review

Highlights from the 2019 North American Cystic Fibrosis Conference

Jordana E Hoppe et al. Pediatr Pulmonol. 2020 Sep.

Abstract

This review briefly summarizes presentations in several major topic areas at the conference: pathophysiology and basic science of cystic fibrosis lung disease, clinical trials, clinical quality improvement, microbiology and treatment of infection, and transition, advanced lung disease and transplant, mental health and psychosocial concerns. The review is intended to highlight several areas and is not a comprehensive summary of the conference. Citations from the conference are by the first author and abstract number or symposium number, as designated in the supplement.

Keywords: DNA/RNA technologies; clinical trials; cystic fibrosis (CF); microbiology; quality improvement.

PubMed Disclaimer

References

REFERENCES

    1. The 33rd Annual North American Cystic Fibrosis Conference, October 31-November 2. Pediatr Pulmonol. 2019;54(suppl):S1-S480.
    1. Martiniano SL, Daines CL, Dellon EP, et al. Highlights from the 2018 North American cystic fibrosis conference. Pediatr Pulmonol. 2019;54:941-948.
    1. Finkel RS, Mercuri E, Darras BT, et al. Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N Engl J Med. 2017;377:1723-1732.
    1. Bennett EM, Anand R, Allan PW, et al. Designer gene therapy using an Escherichia coli purine nucleoside phosphorylase/prodrug system. Chem Biol. 2003;10:1173-1181.
    1. Middleton PG, Mall MA, Drevinek P, et al. Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele. N Engl J Med. 2019;381:1809-1819.